The simplified follicular lymphoma PRIMA‐prognostic index is useful in patients with first‐line chemo‐free rituximab‐based therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The simplified follicular lymphoma PRIMA‐prognostic index is useful in patients with first‐line chemo‐free rituximab‐based therapy

Published:2020-05-14 Issue:5 Volume:191 Page:738-747
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br. J. Haematol.

Author:

Kimby Eva¹^ORCID,Lockmer Sandra¹²,Holte Harald³⁴^ORCID,Hagberg Hans⁵,Wahlin Björn E.¹²,Brown Peter⁶,Østenstad Bjørn³

Affiliation:

1. Unit of Hematology Department of Medicine at Huddinge Karolinska Institutet Stockholm Sweden

2. Unit of Hematology Karolinska University Hospital Stockholm Sweden

3. Department of Oncology Oslo University Hospital Oslo Norway

4. KG Jebsen Center for B‐Cell Malignancies Oslo Norway

5. Department of Oncology Academic Hospital Uppsala Sweden

6. Department of Hematology Rigshospitalet Copenhagen Denmark

Funder

Stockholms Läns Landsting

F. Hoffmann-La Roche

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16692

Reference31 articles.

1. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial

2. Follicular lymphoma: 2018 update on diagnosis and management

3. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

4. Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma

5. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gene expression and copy number profiling of follicular lymphoma biopsies from patients treated with first-line rituximab without chemotherapy;Leukemia & Lymphoma;2023-09-08

2. Personalised therapy in follicular lymphoma – is the dial turning?;Hematological Oncology;2023-07-22

3. The prognostic index PRIMA-PI combined with Ki67 as a better predictor of progression of disease within 24 months in follicular lymphoma;Frontiers in Oncology;2023-06-23

4. Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma;HemaSphere;2023-01-24

5. Should PRIMA Prognostic Index Be Widely Applied Instead of FLIPI2 in the Prognosis of Follicular Lymphoma?;Clinical Cancer Investigation Journal;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3